Patent ID: 7759348

Claim:
A method of treating a skin disorder mediated by stearoyl-CoA desaturase (SCD) in a mammal selected from the group consisting of acne, rosacea, seborrheic skin, and a combination thereof, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I): wherein: x and y are each independently 1; W is —C(O)N(R 1 )—; —C(O)N[C(O)R 1a ]—, —N(R 1 )C(O)N(R 1 )— or —N(R 1 )C(O)—; V is —C(O)—, —C(S)—, or —C(R 10 )H; each R 1 is independently selected from the group consisting of hydrogen; C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halo, methyl or trifluoromethyl; and C 2 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of methoxy and hydroxyl; R 1a is selected from the group consisting of hydrogen, C 1 -C 6 alkyl and cycloalkyl; R 2 is selected from the group consisting of C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 hydroxyalkyl, C 2 -C 12 hydroxyalkenyl, C 1 -C 12 alkoxy, C 2 -C 12 alkoxyalkyl, C 3 -C 12 cycloalkyl, C 4 -C 12 cycloalkylalkyl, aryl, C 7 -C 12 aralkyl, C 3 -C 12 heterocyclyl, C 3 -C 12 heterocyclylalkyl, C 1 -C 12 heteroaryl, and C 3 -C 12 heteroarylalkyl; or R 2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other; R 3 is selected from the group consisting of C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 hydroxyalkyl, C 2 -C 12 hydroxyalkenyl, C 1 -C 12 alkoxy, C 2 -C 12 alkoxyalkyl, C 3 -C 12 cycloalkyl, C 4 -C 12 cycloalkylalkyl, aryl, C 7 -C 12 aralkyl, C 3 -C 12 heterocyclyl, C 3 -C 12 heterocyclylalkyl, C 1 -C 12 heteroaryl and C 3 -C 12 heteroarylalkyl; or R 3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other; R 4 and R 5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or —N(R 12 ) 2 ; R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 , and R 9a are each independently selected from hydrogen or C 1 -C 3 alkyl; or R 6 and R 6a together, or R 7 and R 7a together, or R 8 and R 8a together or R 9 and R 9a together are an oxo group, provided that when V is —C(O)—, R 7 and R 7a together, or R 8 and R 8a together, do not form an oxo group; or one of R 6 , R 6a , R 7 , and R 7a together with one of R 8 , R 8a , R 9 and R 9a form an alkylene bridge; R 10 is hydrogen or C 1 -C 3 alkyl; and each R 12 is independently selected from hydrogen or C 1 -C 6 alkyl; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.